[go: up one dir, main page]

TR201908265T4 - Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. - Google Patents

Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. Download PDF

Info

Publication number
TR201908265T4
TR201908265T4 TR2019/08265T TR201908265T TR201908265T4 TR 201908265 T4 TR201908265 T4 TR 201908265T4 TR 2019/08265 T TR2019/08265 T TR 2019/08265T TR 201908265 T TR201908265 T TR 201908265T TR 201908265 T4 TR201908265 T4 TR 201908265T4
Authority
TR
Turkey
Prior art keywords
inhibitors
heat shock
dihydrodioxine
fused
derivatives
Prior art date
Application number
TR2019/08265T
Other languages
English (en)
Inventor
Jones Keith
Rye Carl
Chessum Nicola
Cheeseman Matthew
Elisa Pasqua Adele
Gordon Pike Kurt
Frank Faulder Paul
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of TR201908265T4 publication Critical patent/TR201908265T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, A1, A2 R4 ve Q?nun burada tanımlanan gibi olduğu formülün (I) bileşikleri ile ilgilidir. Mevcut buluş bileşikleri, ısı şok faktörü 1?in (HSF1) inhibitörleridir. Mevcut buluş özellikle, bu bileşiklerin kanser gibi proliferatif hastalıkların tedavisine ve/veya önlenmesine yönelik terapötik ajanlar olarak kullanımı ile ilgilidir. Mevcut buluş aynı zamanda, bu bileşiklerin hazırlanışına yönelik prosesler ve bunları içeren farmasötik bileşimler ile ilgilidir.
TR2019/08265T 2013-10-04 2014-10-03 Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. TR201908265T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317609.4A GB201317609D0 (en) 2013-10-04 2013-10-04 Inhibitor compounds

Publications (1)

Publication Number Publication Date
TR201908265T4 true TR201908265T4 (tr) 2019-06-21

Family

ID=49630211

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08265T TR201908265T4 (tr) 2013-10-04 2014-10-03 Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.

Country Status (20)

Country Link
US (5) US9701664B2 (tr)
EP (2) EP3052492B1 (tr)
JP (2) JP6500017B2 (tr)
KR (1) KR102332232B1 (tr)
CN (1) CN105814040B (tr)
AU (1) AU2014330940B2 (tr)
BR (1) BR112016007329B1 (tr)
CA (1) CA2925182C (tr)
DK (2) DK3521286T3 (tr)
ES (2) ES2902124T3 (tr)
GB (1) GB201317609D0 (tr)
IL (1) IL244452B (tr)
MX (1) MX369952B (tr)
PL (2) PL3521286T3 (tr)
PT (2) PT3052492T (tr)
RU (1) RU2671979C2 (tr)
SG (1) SG11201602547PA (tr)
TR (1) TR201908265T4 (tr)
WO (1) WO2015049535A1 (tr)
ZA (1) ZA201601223B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) * 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) * 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
WO2018162312A1 (en) 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
WO2019043208A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
KR20220084104A (ko) * 2019-10-17 2022-06-21 바이엘 악티엔게젤샤프트 (4r,4s)-4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복스아미드를 제조하기 위한 광화학 방법
US20240398788A1 (en) 2021-10-06 2024-12-05 Institute Of Cancer Research Methods of treating cancer using hsf1 pathway inhibitors
WO2023111005A1 (en) 2021-12-14 2023-06-22 Wmt Ag Carboxamide substituted heteroaromatic compounds for treating cancer
JP2025511974A (ja) 2022-04-05 2025-04-16 ヴェーエムテー アーゲー がんの治療のためのラクテート／ＡＴＰ産生阻害剤としてのＮ－（３－（ベンゾ［ｂ］チオフェン－２－カルボキシアミド）－フェニル）－２，３－ジヒドロベンゾ［ｂ］［１，４］ジオキシン－６－カルボキシアミド誘導体及び関連化合物
WO2024206776A1 (en) 2023-03-31 2024-10-03 Nuvectis Pharma, Inc. Methods of treating cancer using hsf1 pathway inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137805A (en) 1988-03-18 1992-08-11 The General Hospital Corporation Method of diagnosing stress condition by specific binding of human heat shock factor
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
AU656350B2 (en) 1990-11-26 1995-02-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Cell stress transcriptional factors
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
DE69831950T2 (de) 1997-06-27 2006-07-20 Kaneka Corp. Inhibitoren des hitzeschock-faktors
ES2234169T3 (es) 1997-12-23 2005-06-16 Warner-Lambert Company Llc Compuestos de tiourea, composiciones y procedimientos de tratamiento o prevencion de enfermedades inflamatorias y ateroesclerosis.
WO1999059959A1 (en) 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
TR200100300T2 (tr) 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
DK1115707T3 (da) 1998-09-25 2004-03-01 Astrazeneca Ab Benzamidderivater og deres anvendelse som cytokininhibitorer
PL200804B1 (pl) 1999-03-17 2009-02-27 Astrazeneca Ab Pochodne amidowe, sposoby ich wytwarzania, ich kompozycje farmaceutyczne oraz ich zastosowanie
EP1165092A1 (en) 1999-03-22 2002-01-02 Charterhouse Therapeutics Ltd. Cyclopentanone derivatives and their use
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7405080B2 (en) 2000-03-23 2008-07-29 Voellmy Richard W Compositions and methods relating to prevention of chemotherapy-induced alopecia
KR100804564B1 (ko) 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
WO2003020227A1 (en) 2001-09-03 2003-03-13 Richard Voellmy Compositions and methods relating to prevention of chemotherapy-induced alopecia
AU2003281198A1 (en) 2002-07-04 2004-01-23 Mitsui Chemicals, Inc. m-PHENYLENEDIAMINE DERIVATIVE
NZ537858A (en) 2002-07-15 2008-04-30 Myriad Genetics Inc Compounds, compositions, and methods employing same
GB0218260D0 (en) 2002-08-06 2002-09-11 Charterhouse Therapeutics Ltd Improvements in pharmaceutically useful compounds
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
CA2497951A1 (en) 2002-09-05 2004-03-18 Scios Inc. Treatment of pain by inhibition of p38 map kinase
WO2004024083A2 (en) 2002-09-11 2004-03-25 University Of Medicine And Dentistry Of New Jersey Methods of bone healing
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
US20060100245A1 (en) 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
EP3305919A1 (en) 2003-06-10 2018-04-11 The Trustees of Boston University Detection methods for disorders of the lung
CA2532313A1 (en) 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Medicament for treatment of dermal pigmentation
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005042496A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives and methods for inhibiting heparanase activity
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
MX2007004480A (es) * 2004-10-15 2007-05-08 Astrazeneca Ab Quinoxalinas como inhibidores b raf.
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20090062222A1 (en) 2005-09-29 2009-03-05 Trustees Of Boston University Methods for Sensitizing Cancer Cells to Inhibitors
JP5225857B2 (ja) 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
EP1830289A1 (en) 2005-11-30 2007-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carninoma classification and prognosis
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
BRPI0716560A2 (pt) 2006-09-11 2013-10-01 Syngenta Participations Ag composto, mÉtodo para o combate e controle de insetos, Ácaros, nematàdeos ou moluscos, e, composiÇço inseticida, acaricida, nematicida ou moluscicida
US9353415B2 (en) 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US8518649B2 (en) 2007-04-04 2013-08-27 {hacek over (S)}árka O. Southern Systems and methods for analyzing persistent homeostatic perturbations
WO2008152013A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
CN101896461A (zh) 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US20110166038A1 (en) 2008-06-03 2011-07-07 Screening Methods For Heat-Shock Response Modulatiors Screening methods for heat-shock response modulators
NZ590385A (en) 2008-06-26 2012-11-30 Dana Farber Cancer Inst Inc Signatures and determinants associated with metastasis and methods of use thereof
UA38601U (en) * 2008-07-17 2009-01-12 Львовский Национальный Медицинский Университет Имени Данилы Галицкого 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
WO2010040097A1 (en) 2008-10-02 2010-04-08 Gaia Medical Institute Health test for a broad spectrum of health problems
WO2010043631A1 (en) 2008-10-17 2010-04-22 Universite Libre De Bruxelles Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2010077642A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP5642714B2 (ja) 2009-02-11 2014-12-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規なアミノアザヘテロ環式カルボキサミド
KR101630432B1 (ko) 2009-08-28 2016-06-15 한국생명공학연구원 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
CN102686729B (zh) 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
WO2012027609A2 (en) 2010-08-25 2012-03-01 The Board Of Trustees Of The University Of Illinois Extracts from pirin+ and pirin- plants and uses thereof
EP2439194A1 (en) * 2010-10-05 2012-04-11 Rheinische Friedrich-Wilhelms Universität Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
US9746470B2 (en) 2011-05-09 2017-08-29 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
WO2013006495A2 (en) 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
MX2014002536A (es) 2011-09-02 2014-09-01 Novartis Ag Composiciones organicas para tratar enfermedades relacionadas con el factor de choque de calor 1 (hsf1).
WO2013052888A1 (en) 2011-10-06 2013-04-11 Whitehead Institute For Biomedical Research Hsf 1 as a marker in tumor prognosis and treatment
EP2877859A4 (en) 2012-05-03 2016-08-03 Whitehead Biomedical Inst HSF1 AND HSF1 CSS GENES AND USES THEREOF
KR101507221B1 (ko) 2012-05-14 2015-03-31 이화여자대학교 산학협력단 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound

Also Published As

Publication number Publication date
US11124501B2 (en) 2021-09-21
RU2671979C2 (ru) 2018-11-08
MX369952B (es) 2019-11-27
CN105814040B (zh) 2019-07-30
JP2016531891A (ja) 2016-10-13
RU2016117056A3 (tr) 2018-05-29
PT3052492T (pt) 2019-06-27
EP3521286B1 (en) 2021-09-29
IL244452B (en) 2020-06-30
ZA201601223B (en) 2020-08-26
KR102332232B1 (ko) 2021-11-29
US20240254110A1 (en) 2024-08-01
JP2019135234A (ja) 2019-08-15
MX2016004114A (es) 2016-06-06
RU2016117056A (ru) 2017-11-10
SG11201602547PA (en) 2016-04-28
GB201317609D0 (en) 2013-11-20
AU2014330940A1 (en) 2016-03-03
EP3052492A1 (en) 2016-08-10
US10189821B2 (en) 2019-01-29
US20160289216A1 (en) 2016-10-06
EP3052492B1 (en) 2019-03-27
DK3052492T3 (da) 2019-05-06
BR112016007329A2 (pt) 2017-08-01
CA2925182C (en) 2022-10-04
AU2014330940B2 (en) 2018-03-15
CN105814040A (zh) 2016-07-27
WO2015049535A1 (en) 2015-04-09
ES2902124T3 (es) 2022-03-25
PL3521286T3 (pl) 2022-03-21
KR20160065950A (ko) 2016-06-09
HK1224285A1 (en) 2017-08-18
EP3521286A1 (en) 2019-08-07
ES2730705T3 (es) 2019-11-12
BR112016007329B1 (pt) 2021-02-02
PT3521286T (pt) 2021-12-30
US20170037036A1 (en) 2017-02-09
IL244452A0 (en) 2016-04-21
JP6732071B2 (ja) 2020-07-29
US11787786B2 (en) 2023-10-17
JP6500017B2 (ja) 2019-04-10
CA2925182A1 (en) 2015-04-09
PL3052492T3 (pl) 2019-09-30
US20220220097A1 (en) 2022-07-14
DK3521286T3 (da) 2021-12-06
US20190106413A1 (en) 2019-04-11
US9701664B2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX373324B (es) Compuestos piridínicos de pladienolida y métodos de uso.
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201990399A1 (ru) Соединения, композиции и их применение
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
BR112015032262A2 (pt) composições de nanopartículas e formulações de compostos de piperazina
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.